The FDA has granted approval for dupilumab for the treatment of eosinophilic esophagitis for adult and pediatric patients aged 12 years and older, according to a press release.
Dupilumab (Dupixent, Sanofi; Regeneron Pharmaceuticals, Inc.) is the first drug in the U.S. specifically indicated for the treatment of this condition.
Body weight has emerged as a potential clinical predictor of reduced symptomatic, endoscopic, and histologic response to topical steroid therapy in patients with eosinophilic esophagitis.
In a phase 3 trial of adults and adolescents with hard-to-treat eosinophilic esophagitis, 6 months of weekly dupilumab sent 59% of participants into disease remission.